DK1427720T3 - 3-substitueret-4-pyrimidonderivater - Google Patents
3-substitueret-4-pyrimidonderivaterInfo
- Publication number
- DK1427720T3 DK1427720T3 DK02772871T DK02772871T DK1427720T3 DK 1427720 T3 DK1427720 T3 DK 1427720T3 DK 02772871 T DK02772871 T DK 02772871T DK 02772871 T DK02772871 T DK 02772871T DK 1427720 T3 DK1427720 T3 DK 1427720T3
- Authority
- DK
- Denmark
- Prior art keywords
- sup
- sub
- substituted
- ring
- group
- Prior art date
Links
- -1 3-substituted-4-pyrimidone Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical group C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000008318 pyrimidones Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 108010061506 tau-protein kinase Proteins 0.000 abstract 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001331675 | 2001-09-21 | ||
| JP2001331678 | 2001-09-21 | ||
| JP2001331677 | 2001-09-21 | ||
| JP2001331674 | 2001-09-21 | ||
| PCT/JP2002/009685 WO2003037888A1 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1427720T3 true DK1427720T3 (da) | 2009-05-04 |
Family
ID=27482651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02772871T DK1427720T3 (da) | 2001-09-21 | 2002-09-20 | 3-substitueret-4-pyrimidonderivater |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7427615B2 (da) |
| EP (1) | EP1427720B1 (da) |
| JP (1) | JP4347050B2 (da) |
| KR (1) | KR100881821B1 (da) |
| CN (1) | CN100488958C (da) |
| AT (1) | ATE424393T1 (da) |
| AU (1) | AU2002337499B2 (da) |
| BR (1) | BR0212892A (da) |
| CA (1) | CA2460121C (da) |
| CY (1) | CY1110317T1 (da) |
| DE (1) | DE60231414D1 (da) |
| DK (1) | DK1427720T3 (da) |
| EA (1) | EA007576B1 (da) |
| ES (1) | ES2323576T3 (da) |
| HU (1) | HUP0401900A3 (da) |
| IL (2) | IL160700A0 (da) |
| MX (1) | MXPA04002662A (da) |
| NO (1) | NO325781B1 (da) |
| NZ (1) | NZ531636A (da) |
| PL (1) | PL368671A1 (da) |
| PT (1) | PT1427720E (da) |
| SI (1) | SI1427720T1 (da) |
| TW (1) | TWI265164B (da) |
| WO (1) | WO2003037888A1 (da) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR023052A1 (es) | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
| IL160701A0 (en) | 2001-09-21 | 2004-08-31 | Mitsubishi Pharma Corp | 3-substituted-4-pyrimidone derivatives |
| JP4616003B2 (ja) * | 2002-12-16 | 2011-01-19 | 田辺三菱製薬株式会社 | ３−置換−４−ピリミドン誘導体 |
| US20040242568A1 (en) | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| TWI357408B (en) * | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
| MXPA06001601A (es) | 2003-08-13 | 2006-08-25 | Takeda Pharmaceutical | Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa. |
| WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| CN102079743B (zh) | 2004-03-15 | 2020-08-25 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| AR050865A1 (es) | 2004-09-09 | 2006-11-29 | Sanofi Aventis | Derivados de 2- morfolino-4-pirimidona |
| BRPI0515851A (pt) * | 2004-09-29 | 2008-08-12 | Mitsubishi Pharma Corp | composto de pirimidona |
| CN101084198A (zh) * | 2004-10-15 | 2007-12-05 | 阿斯利康(瑞典)有限公司 | 取代的氨基－嘧啶酮及其用途 |
| US20090221579A1 (en) * | 2004-10-15 | 2009-09-03 | Jeffrey Scott Albert | Substituted Amino-Compounds and Uses Thereof |
| JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| NZ566799A (en) | 2005-09-14 | 2011-04-29 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
| WO2007035629A2 (en) | 2005-09-16 | 2007-03-29 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
| TW200813015A (en) * | 2006-03-15 | 2008-03-16 | Mitsubishi Pharma Corp | 2-(cyclic amino)-pyrimidone derivatives |
| CA2661334C (en) * | 2006-08-23 | 2011-11-29 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| AR064660A1 (es) | 2006-12-26 | 2009-04-15 | Mitsubishi Tanabe Pharma Corp | Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| CN101842371A (zh) * | 2007-09-14 | 2010-09-22 | 赛诺菲-安万特公司 | 3-甲基-2-((2S)-2-(4-(3-甲基-1,2,4-噁二唑-5-基)苯基)吗啉基)-6-(嘧啶-4-基)嘧啶-4(3H)-酮作为tau蛋白激酶抑制剂 |
| MX2010002765A (es) | 2007-09-14 | 2010-05-19 | Mitsubishi Tanabe Pharma Corp | Derivado de 6-pirimidinil-pirimid-4-ona. |
| AR076014A1 (es) | 2009-04-02 | 2011-05-11 | Sanofi Aventis | Derivados de 3- (1,4) oxazepan -4-pirimidona |
| US9006232B2 (en) | 2009-08-13 | 2015-04-14 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives |
| JP5442852B2 (ja) | 2009-08-13 | 2014-03-12 | 田辺三菱製薬株式会社 | タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体 |
| WO2013071232A1 (en) * | 2011-11-11 | 2013-05-16 | Beta Cat Pharmaceuticals, Llc | Compositions and methods for inhibition of tbl-1 binding to disease-associated molecules |
| JP6898229B6 (ja) | 2014-09-29 | 2021-07-28 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲアンタゴニスト製造における方法及び中間体 |
| SG11201805828YA (en) | 2016-01-14 | 2018-08-30 | Chemocentryx Inc | Method of treating c3 glomerulopathy |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4935631B1 (da) | 1970-12-28 | 1974-09-25 | ||
| JPS559099B2 (da) | 1972-08-07 | 1980-03-07 | ||
| JPS4935633A (da) | 1972-08-09 | 1974-04-02 | ||
| JPS5124008B2 (da) | 1972-08-10 | 1976-07-21 | ||
| JPS4935632A (da) | 1972-08-10 | 1974-04-02 | ||
| JPS5271481A (en) | 1975-12-10 | 1977-06-14 | Yoshitomi Pharmaceut Ind Ltd | Synthesis of pyridylpyrimidines |
| JPS52139085A (en) | 1976-05-13 | 1977-11-19 | Hokuriku Pharmaceutical | 22allylpiperazine derivative and method for its preparation |
| US4507302A (en) | 1979-03-19 | 1985-03-26 | The Upjohn Company | Method for treating arthritis with 6-aryl pyrimidine compounds |
| US4619933A (en) | 1979-09-28 | 1986-10-28 | The Upjohn Company | 6-aryl pyrimidines for treating aplastic anemia |
| US4725600A (en) | 1984-07-13 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent |
| EP0354179B1 (de) | 1988-07-29 | 1994-08-17 | Ciba-Geigy Ag | Thiouracile als Stabilisatoren für chlorhaltige Polymerisate |
| WO1993011231A1 (en) | 1991-12-06 | 1993-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| DE4206145A1 (de) | 1992-02-28 | 1993-09-02 | Basf Ag | Herbizide n-((pyrimidin-2-yl)aminocarbonyl)benzolfulfonamide |
| JP3324611B2 (ja) | 1992-07-03 | 2002-09-17 | 三菱化学株式会社 | タウ蛋白質のリン酸化方法 |
| US5300477A (en) * | 1992-07-17 | 1994-04-05 | Rohm And Haas Company | 2-arylpyrimidines and herbicidal use thereof |
| JPH06329551A (ja) | 1993-03-22 | 1994-11-29 | Mitsubishi Kasei Corp | アルツハイマー病の予防または治療薬およびそのスクリーニング方法 |
| JPH07179442A (ja) * | 1993-10-08 | 1995-07-18 | Sagami Chem Res Center | ４−イミノオキサゾリジン−２−オン誘導体、それらの製造方法、及びそれらを有効成分とする除草剤 |
| NZ274978A (en) | 1993-10-12 | 1998-04-27 | Du Pont Merck Pharma | 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof |
| JP2002514195A (ja) * | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジン化合物およびそれの使用 |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
| AR048564A1 (es) | 1996-12-05 | 2006-05-10 | Amgen Inc | Compuestos de pirimidina sustituidos,composicion farmaceutica y usos para la fabricacion de medicamentos particularmente para el tratamiento de enfermedades mediadas por tnf-alfa, il-1 beta, il-6 y/o il-8 |
| AR023052A1 (es) * | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
| YU63802A (sh) | 2000-02-25 | 2005-06-10 | F. Hoffmann-La Roche Ag. | Modulatori adenozinskih receptora |
| EP1136482A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| AU2001262150A1 (en) | 2000-03-23 | 2001-10-03 | Mitsubishi Pharma Corporation | 2-(nitrogen-heterocyclic)pyrimidone derivatives |
| IL160701A0 (en) | 2001-09-21 | 2004-08-31 | Mitsubishi Pharma Corp | 3-substituted-4-pyrimidone derivatives |
| JP4616003B2 (ja) | 2002-12-16 | 2011-01-19 | 田辺三菱製薬株式会社 | ３−置換−４−ピリミドン誘導体 |
| TWI357408B (en) | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
-
2002
- 2002-09-20 EP EP02772871A patent/EP1427720B1/en not_active Expired - Lifetime
- 2002-09-20 CN CNB028184696A patent/CN100488958C/zh not_active Expired - Fee Related
- 2002-09-20 WO PCT/JP2002/009685 patent/WO2003037888A1/en not_active Ceased
- 2002-09-20 PL PL02368671A patent/PL368671A1/xx unknown
- 2002-09-20 HU HU0401900A patent/HUP0401900A3/hu unknown
- 2002-09-20 AT AT02772871T patent/ATE424393T1/de active
- 2002-09-20 TW TW091121655A patent/TWI265164B/zh not_active IP Right Cessation
- 2002-09-20 DE DE60231414T patent/DE60231414D1/de not_active Expired - Lifetime
- 2002-09-20 IL IL16070002A patent/IL160700A0/xx unknown
- 2002-09-20 KR KR1020047004112A patent/KR100881821B1/ko not_active Expired - Fee Related
- 2002-09-20 SI SI200230816T patent/SI1427720T1/sl unknown
- 2002-09-20 NZ NZ531636A patent/NZ531636A/en not_active IP Right Cessation
- 2002-09-20 PT PT02772871T patent/PT1427720E/pt unknown
- 2002-09-20 BR BR0212892-6A patent/BR0212892A/pt not_active Application Discontinuation
- 2002-09-20 ES ES02772871T patent/ES2323576T3/es not_active Expired - Lifetime
- 2002-09-20 MX MXPA04002662A patent/MXPA04002662A/es active IP Right Grant
- 2002-09-20 EA EA200400453A patent/EA007576B1/ru not_active IP Right Cessation
- 2002-09-20 JP JP2003540169A patent/JP4347050B2/ja not_active Expired - Fee Related
- 2002-09-20 CA CA2460121A patent/CA2460121C/en not_active Expired - Fee Related
- 2002-09-20 DK DK02772871T patent/DK1427720T3/da active
- 2002-09-20 US US10/489,606 patent/US7427615B2/en not_active Expired - Fee Related
- 2002-09-20 AU AU2002337499A patent/AU2002337499B2/en not_active Ceased
-
2004
- 2004-03-03 IL IL160700A patent/IL160700A/en not_active IP Right Cessation
- 2004-04-20 NO NO20041600A patent/NO325781B1/no not_active IP Right Cessation
-
2009
- 2009-05-28 CY CY20091100562T patent/CY1110317T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI265164B (en) | 2006-11-01 |
| WO2003037888A1 (en) | 2003-05-08 |
| SI1427720T1 (sl) | 2009-08-31 |
| KR100881821B1 (ko) | 2009-02-03 |
| IL160700A (en) | 2009-09-22 |
| CY1110317T1 (el) | 2015-01-14 |
| EP1427720B1 (en) | 2009-03-04 |
| NZ531636A (en) | 2005-11-25 |
| CA2460121C (en) | 2010-11-02 |
| ES2323576T3 (es) | 2009-07-21 |
| CN1556804A (zh) | 2004-12-22 |
| IL160700A0 (en) | 2004-08-31 |
| NO325781B1 (no) | 2008-07-14 |
| DE60231414D1 (de) | 2009-04-16 |
| CN100488958C (zh) | 2009-05-20 |
| KR20040054689A (ko) | 2004-06-25 |
| JP2005510506A (ja) | 2005-04-21 |
| JP4347050B2 (ja) | 2009-10-21 |
| PT1427720E (pt) | 2009-04-27 |
| PL368671A1 (en) | 2005-04-04 |
| CA2460121A1 (en) | 2003-05-08 |
| EP1427720A1 (en) | 2004-06-16 |
| EA200400453A1 (ru) | 2004-08-26 |
| HUP0401900A2 (hu) | 2004-12-28 |
| EA007576B1 (ru) | 2006-12-29 |
| US20050090490A1 (en) | 2005-04-28 |
| ATE424393T1 (de) | 2009-03-15 |
| NO20041600L (no) | 2004-06-16 |
| MXPA04002662A (es) | 2004-11-22 |
| US7427615B2 (en) | 2008-09-23 |
| BR0212892A (pt) | 2004-08-03 |
| HUP0401900A3 (en) | 2005-08-29 |
| AU2002337499B2 (en) | 2007-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60231414D1 (de) | 3-substituierte 4-pyrimidonderivate | |
| EA200400452A1 (ru) | Производные 3-замещенных 4-пиримидонов | |
| NO20060219L (no) | Forbindelser | |
| EA200601235A1 (ru) | Производные тиазола | |
| GB2393653A (en) | DNA-PK inhibitors | |
| ES2166359T3 (es) | Derivado de depsipeptido, su produccion y uso. | |
| MY146532A (en) | Thiazole derivative | |
| ATE472535T1 (de) | Pyrimidinmatrixmetalloproteinaseinhibitoren | |
| MXPA05012033A (es) | Compuesto de pirimidina y composicion para el control de plagas que contiene el mismo. | |
| CY1108269T1 (el) | Παραγωγα της αβερμεκτινης β1 που εχουν εναν αμινοσουλφονυλοξυ υποκαταστατη στη θεση 4" | |
| TW200510338A (en) | 3-substituted-4-pyrimidone derivatives | |
| DK1008592T3 (da) | Cykliske amidderivater, som inhiberer cathepsin K | |
| ID25649A (id) | Turunan-turunan sikloalkena, produksi serta penggunaannya | |
| TW200612920A (en) | Novel imidazolidine derivatives | |
| EA200500984A1 (ru) | Производные 3-замещённого-4-пиримидона | |
| TW200613297A (en) | Pyrazole derivatives | |
| ATE550332T1 (de) | 4-imidazolin-2-onverbindungen als p38-map- kinaseinhibitors | |
| BR0308759A (pt) | Derivados de fenil amidas siliconadas utilizáveis como microbiocida | |
| TW200609218A (en) | Bicyclic compounds | |
| DE60108089D1 (de) | Heterozyclische oder benzol derivate von liponsäure, deren herstellung und deren verwendung als heilmittel | |
| ATE296633T1 (de) | Thiopyran-4-one als inhibitoren der dna protein kinase | |
| KR970021067A (ko) | 1-아지닐-테트라졸리논 | |
| DK1899331T3 (da) | Homomorpholinoxazolidnoner som antibakterielle midler | |
| TW200740757A (en) | Carboxamide compound and use of the same | |
| TW200738679A (en) | Carboxamide compound and use of the same |